Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

An Evaluation of Patient Reported Outcomes and Clinical Outcomes

NCT06092970 · View on ClinicalTrials.gov ↗

Study Summary

This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: * Patient reported outcomes (PRO), using the EQ-5D questionnaire * Clinical outcomes

Interventions

  • DRUG Placebo
  • DRUG RBT-1

Study Locations (20)

Michigan

  • Research Site — Ann Arbor
  • Research Site — Lansing
  • Research Site — Midland
  • Research Site — Royal Oak

Indiana

  • Research Site — Fort Wayne
  • Research Site — Indianapolis
  • Research Site — Indianapolis

California

  • Research Site — San Francisco
  • Research Site — Stanford

Florida

  • Research Site — Atlantis
  • Research Site — Gainesville

Georgia

  • Research Site — Athens
  • Research Site — Atlanta

Alabama

  • Research Site — Huntsville

District of Columbia

  • Research Site — Washington D.C.

Kansas

  • Research Site — Kansas City

Trial Details

FieldValue
Enrollment Target 379 participants
Start Date 2023-10-16
Est. Completion 2026-06-30

Sponsor

Renibus Therapeutics

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06092970

The ClinicalTrials.gov registry entry for NCT06092970 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 379 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renibus Therapeutics, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Post-Operative Complications in Cardiac Surgery appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06092970 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Michigan, Indiana, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06092970 about?

NCT06092970 is a clinical study titled "An Evaluation of Patient Reported Outcomes and Clinical Outcomes". This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: * Patient reported outcomes (PRO), using the EQ-5D questionnaire * Clinical outcomes

What is the current status of trial NCT06092970?

This trial is currently active not recruiting. The enrollment target is 379 participants. The study started on 2023-10-16. Estimated completion is 2026-06-30.

What conditions does trial NCT06092970 study?

This clinical trial studies the following conditions: Post-Operative Complications in Cardiac Surgery. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06092970?

The interventions under investigation include: Placebo (DRUG), RBT-1 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06092970?

This trial is sponsored by Renibus Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06092970 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial